I-GENE · Project

Laser-Controlled Gene Editing Technology for Safer Cancer and Genetic Treatments

healthPrototypeTRL 4Thin data (2/5)

Imagine you could fix a typo in a book — but the book is your DNA, and one wrong edit could cause serious harm. Current gene-editing tools like CRISPR work like a search-and-replace function, but sometimes they "fix" the wrong word. I-GENE built tiny particles called nanotransducers that only make the edit when you shine a laser on them, giving doctors a remote control: editing happens only when, where, and if the conditions are exactly right. They proved it works in zebrafish embryos and tested it against melanoma in mice.

By the numbers

3 billion

Base pairs in human genome that the technology must navigate to find the right target

Consortium partners collaborating on the technology

Countries represented in the consortium (IT, NL, PL, UK)

SME partners involved in development

Total project deliverables produced

The business problem

What needed solving

Current gene-editing tools like CRISPR can accidentally modify the wrong parts of a patient's DNA, creating dangerous off-target effects that have stalled clinical development and caused safety concerns in trials. There is no reliable way to control exactly when, where, and under what conditions a gene edit happens inside a living organism. This unpredictability makes pharma and biotech companies hesitant to invest heavily in gene therapy pipelines.

The solution

What was built

The project built laser-activated nanotransducers that enable gene editing with triple safety control: temporal (only when the laser is on), spatial (only where the laser is focused), and conditional (only if the correct target is recognized). Concrete outputs include a lab-on-chip system for detecting cells in microfluidic channels (delivered by partner LIONIX) and 19 total deliverables including a final technology showcase conference.

Audience

Who needs this

Gene therapy companies struggling with off-target editing effects in their drug pipelinesMedical device firms building precision laser or photonics-based therapeutic toolsPharmaceutical R&D departments investing in next-generation cancer treatmentsLab-on-chip and microfluidics companies looking for new clinical applicationsVeterinary biotech firms exploring safer genetic modification for animal breeding

Business applications

Who can put this to work

Pharmaceutical & Gene Therapy

enterprise

Target: Biotech companies developing gene therapies

If you are a biotech firm struggling with off-target effects in your gene therapy pipeline — this project developed laser-activated nanotransducers that edit genes only when, where, and if the right conditions are met. The technology was validated in zebrafish embryos and a murine melanoma model across a consortium of 6 partners in 4 countries. This could reduce costly clinical trial failures caused by unintended genetic edits.

Medical Devices & Diagnostics

SME

Target: Lab-on-chip and photonics companies

If you are a medical device company working on precision diagnostics or cell-level interventions — this project built a lab-on-chip system for cell detection combined with laser-activated gene editing. The consortium included 3 SME partners with expertise in integrated photonics and nanotechnology. This opens a path toward point-of-care gene editing platforms.

Veterinary & Agricultural Biotech

mid-size

Target: Animal genetics and breeding technology companies

If you are in animal biotech dealing with imprecise genetic modification tools — this project demonstrated controlled gene editing in zebrafish embryos using nanotransducers activated by laser. The spatial and temporal control (editing only when the laser is on, only where it is focused) could translate to safer genetic improvements in livestock or aquaculture breeding programs.

Frequently asked

Quick answers

What would this technology cost to license or integrate?

No pricing or licensing terms are publicly available from the project data. The technology was developed under an EU RIA grant with 6 partners including 3 SMEs, so commercial terms would need to be negotiated with the consortium. Based on available project data, interested parties should contact the University of Pisa as coordinating institution.

Can this scale to industrial or clinical production?

Based on available project data, the technology has been validated at proof-of-concept level in zebrafish embryos and a murine melanoma model. Scaling to clinical use would require further development, likely including human cell line testing and regulatory approval. The project's lab-on-chip cell detection system suggests early steps toward scalable processing.

Who owns the intellectual property?

IP ownership would be shared among the 6 consortium partners across 4 countries (Italy, Netherlands, Poland, UK) according to the EU grant agreement terms. The coordinator, University of Pisa, would be the first point of contact for IP discussions. Specific patent filings are not detailed in available project data.

What regulatory hurdles exist for this technology?

Gene therapy products face stringent regulatory pathways including EMA (Europe) and FDA (US) approval. The project validated in animal models (zebrafish, mice), meaning several years of preclinical and clinical trials would be needed before any human application. The safety advantage — editing only when, where, and if conditions are met — could actually simplify the regulatory argument compared to conventional CRISPR.

How long before this reaches the market?

The project ran from 2019 to 2024 under the FET Open programme, which funds frontier research. Based on the proof-of-concept stage in animal models, realistic market timeline would be 8-12 years for therapeutic applications. Nearer-term applications in research tools or veterinary biotech could emerge sooner.

Can this integrate with existing gene therapy workflows?

The technology uses a fundamentally different activation mechanism (laser + nanotransducers) compared to standard CRISPR delivery. Integration would require new equipment for laser activation and nanotransducer preparation. However, the underlying gene recognition still builds on established CRISPR/Cas9 principles, so existing genomic design tools remain relevant.

Consortium

Who built it

The I-GENE consortium of 6 partners across 4 countries (Italy, Netherlands, Poland, UK) has a strong industry presence at 50%, with 3 SMEs involved. This is unusual for frontier gene-editing research and suggests the technology was designed with commercial translation in mind from the start. The University of Pisa coordinates, backed by 2 research organizations and 3 industry players — including LIONIX, which contributed the lab-on-chip cell detection capability. The mix of academic depth and SME agility positions the results well for spin-off or licensing, though being a FET Open project means the technology is still early-stage.

UNIVERSITA DI PISACoordinator · IT
M-SQUARED LASERS LIMITEDparticipant · UK
PROCHIMIA SURFACES SP. Z O.O.participant · PL
LIONIX INTERNATIONAL BVparticipant · NL
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIAparticipant · IT
CONSIGLIO NAZIONALE DELLE RICERCHEthirdparty · IT

How to reach the team

University of Pisa (Italy) — reach out to the principal investigator through the university's technology transfer office

Order a report on this consortium See UNIVERSITA DI PISA profile →

Next steps

Talk to the team behind this work.

Want an introduction to the I-GENE research team? SciTransfer can connect you with the right people and provide a detailed technology brief tailored to your specific application.

Order a report on this topic More in Health & Biomedical